Provided by Tiger Trade Technology Pte. Ltd.

NanoViricides

1.44
+0.04002.86%
Post-market: 1.460.0200+1.39%17:03 EDT
Volume:305.51K
Turnover:447.37K
Market Cap:36.72M
PE:-3.54
High:1.50
Open:1.43
Low:1.40
Close:1.40
52wk High:2.23
52wk Low:0.8500
Shares:25.50M
Float Shares:24.90M
Volume Ratio:0.81
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4071
EPS(LYR):-0.4071
ROE:-101.46%
ROA:-55.53%
PB:4.23
PE(LYR):-3.54

Loading ...

NanoViricides Announces $3.8 Million Registered Direct Offering

TIPRANKS
·
Jul 30

NanoViricides Issues Warrants Exercisable at Us$1.75 in Us$3.8 Million Registered Direct Offering

Reuters
·
Jul 30

NanoViricides Raises Financing for Trial of Ebola Treatment, Awaits Regulatory Approval in Congo

MT Newswires Live
·
Jul 28

NanoViricides awaits regulatory approval to being Phase II trial of NV-387

TIPRANKS
·
Jul 28

NanoViricides Shares Fall Pre-Bell After $3.8 Million Direct Stock Sale Pricing

MT Newswires Live
·
Jul 24

NanoViricides prices $3.8M registered direct offering

TIPRANKS
·
Jul 24

Nanoviricides Prices Offering with 2,516,339 Warrants at US$ 1.75 Exercise Price

Reuters
·
Jul 24

NanoViricides applies for ACOREP approval to begin Phase II NV-387 trial

TIPRANKS
·
Jul 22

Nanoviricides Seeks DR Congo Regulator Clearance for Phase II Ebola Trial of Nv-387 Oral Gummies

Reuters
·
Jul 22

Nanoviricides, Inc - Applied to Acorep for Approval to Begin Phase Ii Clinical Trial of Nv-387 Oral Gummies as Treatment for Bundibugyo Ebolavirus

THOMSON REUTERS
·
Jul 22

Nanoviricides, Inc: Sufficient Quantity of Nv-387 Oral Gummies Drug Product for Starting Clinical Trial Against Ebola is Already Available in Drc

THOMSON REUTERS
·
Jul 22

NanoViricides Establishes ATM Equity Sales Agreement

TIPRANKS
·
Jul 18

Nanoviricides Wins DRC Ethics Approval for Phase II Trial of Nv-387 Oral Gummies for Ebola

Reuters
·
Jul 13

Nanoviricides Rated Outperform at Noble Capital, Target Price $6

Reuters
·
Jul 08

NanoViricides initiated with an Outperform at Noble Capital

TIPRANKS
·
Jul 06

Nanoviricides, Inc : Noble Capital Initiates Coverage with Outperform Rating; Target Price $6

THOMSON REUTERS
·
Jul 06

Nanoviricides Says FDA Grants Rare Pediatric Disease Designation for Nv-387 Measles Treatment

Reuters
·
Jun 29

NanoViricides ships NV-387 oral gummies to DR Congo for Phase II mpox trial

Reuters
·
Jun 22

NanoViricides files to sell 1.33M shares of common stock for holders

TIPRANKS
·
Jun 16

NanoViricides announces proposal approved by Pillar Committee in DRC

TIPRANKS
·
Jun 15